Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Soumo Banerji

Plastic and Reconstructive Surgery Webster, TX Medical Doctor

NPI 1588829527 CMS profile 2782854

135 Water St, Webster, TX 77598

Open in the dashboard

General payments

$9,834

200 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Soumo Banerji of Webster, TX is reported in the CMS Open Payments database as having received $9,834 across 200 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Plastic and Reconstructive Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,651 64
2024 General $1,448 50
2023 General $640 20
2022 General $403 18
2021 General $2,426 28
2020 General $134 7
2019 General $3,132 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Soumo Banerji
  • Plastic and Reconstructive Surgery median
  • Middle half of Plastic and Reconstructive Surgery
  • National median

In program year 2025, general payments to Soumo Banerji were reported at $1,651. Among 2,070 Plastic and Reconstructive Surgery profiles paid that year, the median was $442 and the middle half received between $150 and $1,242.

Show as a table
Year Soumo Banerji Plastic and Reconstructive Surgery median Middle half National median
2019 $3,132 $335 $121–$1,264 $163
2020 $134 $162 $57–$417 $114
2021 $2,426 $245 $89–$735 $132
2022 $403 $325 $120–$932 $149
2023 $640 $343 $129–$999 $160
2024 $1,448 $390 $141–$1,085 $164
2025 $1,651 $442 $150–$1,242 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $5,080 39 payments
  2. AbbVie, Inc. $2,290 100 payments
  3. Revance Therapeutics, Inc. $974 22 payments
  4. Merz North America, Inc. $653 10 payments
  5. Galderma Laboratories, L.P. $288 11 payments
  6. Tepha Inc $154 1 payment
  7. Stryker Corporation $95 3 payments
  8. Mentor Worldwide LLC $90 3 payments
  9. Pacira Pharmaceuticals Incorporated $46 2 payments
  10. Sientra, Inc. $44 2 payments
  11. Other $118 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,789 194 payments
  2. Gift $2,700 1 payment
  3. Travel and Lodging $1,323 3 payments
  4. Education $22 2 payments
Products named General payments · program years 2019–2025
  1. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastics $4,021 38 payments
  2. NATRELLE $2,743 3 payments
  3. REVOLVE $1,765 9 payments
  4. ALLODERM $1,445 56 payments
  5. DAXXIFY $974 22 payments
  6. Xeomin $305 5 payments
  7. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastic Surgery $227 14 payments
  8. GalaFLEX $154 1 payment
  9. MENTOR MemoryGel Resterilizable Gel Sizer $90 3 payments
  10. BOTOX $60 5 payments
  11. Other $540 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

72

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$342

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

22.2%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Minocycline Hcl Generic 24 $148
Cyclobenzaprine Hcl Generic 32 $100
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 16 $94

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DAXXIFY
  • REVANCE THERAPEUTICS, INC. $432
$432 — —
Xeomin
  • MERZ NORTH AMERICA, INC. $32
$32 — —
BOTOX
  • AbbVie, Inc. $9
$9 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

200 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic and Reconstructive Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record